Ran Nussbaum - Jun 4, 2025 Form 4/A - Amendment Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Director, 10%+ Owner
Signature
/s/ Keith Regnante, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
Jun 4, 2025
Transactions value $
$0
Form type
4/A - Amendment
Date filed
6/11/2025, 07:30 AM
Date Of Original Report
Jun 6, 2025
Previous filing
Jun 3, 2024
Next filing
Sep 11, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Nussbaum Ran Director, 10%+ Owner C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON /s/ Keith Regnante, Attorney-in-Fact 2025-06-11 0001609805

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding KROS Common Stock 155K Jun 4, 2025 See footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are held by Pontifax Late Stage Fund, L.P. ("Late Stage"). Pontifax Late Stage GP Ltd. ("Late Stage GP") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, "Pontifax IV Funds"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds.
F2 Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

Remarks:

The indirect holdings reported herein were inadvertently omitted from the Forms 4 filed on November 30, 2022 and June 6, 2025.